Mattsson, Niklas
Ossenkoppele, Rik
Smith, Ruben
Strandberg, Olof
Ohlsson, Tomas
Jögi, Jonas
Palmqvist, Sebastian
Stomrud, Erik
Hansson, Oskar
Funding for this research was provided by:
European Research Council
Vetenskapsrådet (SE)
Marianne and Marcus Wallenberg foundation
Article History
Received: 21 March 2018
Accepted: 9 July 2018
First Online: 7 August 2018
Ethics approval and consent to participate
: All participants gave written informed consent to participate in the study. Ethical approval was given by the Ethical Committee of Lund University, Lund, Sweden, and all the methods were carried out in accordance with the approved guidelines. Superscript removed F-AV-1451 PET imaging approval was obtained from the Swedish Medicines and Products Agency and the local Radiation Safety Committee at Skåne University Hospital, Sweden.
: Not applicable.
: OH has acquired research support (for the institution) from Roche, GE Healthcare, Biogen, AVID Radiopharmaceuticals, Fujirebio, and Euroimmun. In the past 2 years, he has received consultancy/speaker fees (paid to the institution) from Lilly, Roche, and Fujirebio. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.